Australia’s health tech boom: A new era of patient care and economic growth
In the realm of healthcare, a transformative wave of technological innovation is heralding an era of enhanced employment opportunities, a more sophisticated health infrastructure, and significantly improved patient care outcomes in Australia. This perspective is championed by the Assistant Minister for Health, Ged Kearney, who underscores the dual benefits of advancing health technology – economic growth and healthcare improvement.
According to a revealing independent analysis unveiled by Kearney at Parliament House, each million dollars of investment in this sector is responsible for generating fifty-six new full-time positions. Moreover, this investment yields more than quadruple the gross economic value for every dollar expended, showcasing the substantial economic leverage of health technology advancements.
For years, Australia has grappled with a self-perception of excelling in research while faltering in the commercialisation of innovative ideas. However, this narrative is undergoing a radical change, thanks in part to a flagship initiative. This initiative, buoyed by industry support and the federal medical research future fund, meticulously evaluates the economic impact of digital health advancements in diagnosis, monitoring, and recovery, particularly within the comfort of patients’ homes.
Kearney emphasises the initiative’s role in steering the health system towards offering more personalised and interconnected healthcare solutions. The ANDHealth+ programme exemplifies this approach through its “idea to exit” business accelerator model, which allocates funding and specialised assistance to domestic small and medium-sized enterprises (SMEs) with significant growth prospects.
Bronwyn Le Grice, CEO of ANDHealth, highlights the global impact potential of these technologies, which include innovations for more precise and rapid epilepsy diagnosis, the use of artificial intelligence (AI) in determining the efficacy of eye disease medications, and remote cardiac rehabilitation monitoring by leading cardiologists.
One notable invention is “Oli”, an AI-enhanced wearable device that tracks vital signs to identify expectant mothers at risk of complications during childbirth. This device, named after the founder’s son and produced by Baymatob in Sydney’s inner west, represents the cutting-edge intersection of medical devices and software intelligence.
The programme’s efficacy is underscored by LEK Consulting, which recognises the business model’s potential to address Australia’s commercialisation challenges, suggesting its applicability across various sectors. To date, 850 digital health companies have received support, raising a total of $161.8 million in capital, creating 512 new jobs, conducting numerous clinical trials, reaching over one million patients, and launching 30 products internationally.
With 755 startups still operational, these figures testify to the resilience and success of companies in a challenging landscape for new ventures and investors. The report also notes that companies focusing on diagnostics, monitoring, and screening are leading job creators.
Despite the obstacles of prolonged development phases and the necessity of comprehensive clinical trials for regulatory approval, the sector’s pioneers remain optimistic. Le Grice advocates for supporting innovation, irrespective of its origin, emphasising the importance of evidence-based technologies capable of transforming lives.
This paradigm shift towards integrating health technology into economic strategy not only revitalises patient care but also propels Australia closer to overcoming its commercialisation hurdle, heralding a future where health and wealth are intrinsically linked.
